Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterCorrespondence

A Difficult Case of Polymyalgia Rheumatica

OZGUR ZELIHA KARAAHMET, AJDA BAL, ECE UNLU and AYTUL CAKCI
The Journal of Rheumatology August 2012, 39 (8) 1758; DOI: https://doi.org/10.3899/jrheum.120146
OZGUR ZELIHA KARAAHMET
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: drozguroz@gmail.com
AJDA BAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ECE UNLU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYTUL CAKCI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We read with great interest the article by Mazzantini, et al1 that assessed the occurrence of adverse events in patients with polymyalgia rheumatica (PMR) treated with low-dose glucocorticoids (GC). They found that longterm, low-dose GC treatment of PMR is associated with serious adverse events. PMR is an inflammatory rheumatic disease of elderly people that is characterized by aching and stiffness in shoulder and pelvic girdle. The incidence of PMR increases with age, peaking in the 70 to 80-year age group2. The response to systemic GC therapy is usually rapid but longterm GC treatment may be necessary to maintain clinical improvement. Patients with PMR frequently experience relapses that make management of the disease more difficult. Prolonged GC use can be associated with various adverse events. Methotrexate (MTX) has been proposed as a steroid-sparing drug in treatment of PMR3,4.

We would like to share our experience with an elderly patient with PMR who suffered gastrointestinal (GI) bleeding and used oral anticoagulant therapy because of atrial fibrillation. A man aged 78 years experienced upper GI bleeding after nonsteroidal antiinflammatory drug use for shoulder pain. He had a history of peptic ulcer disease and medication with warfarin for atrial fibrillation. He had stomach ulcer without dysplasia on endoscopic examination. After stabilization for bleeding he was evaluated for shoulder pain. He reported increasing pain and stiffness in his shoulder and pelvic girdle over 1 month. Blood tests showed erythrocyte sedimentation rate (ESR) 69 mm/h, C-reactive protein (CRP) 51 mg/l, white blood cell count 8000/mm3 (reference range 5.2–11.4/mm3), hemoglobin 9.7 g/dl (reference range 13–17 g/dl), and platelet count 285,000/mm3 (reference range 130,000–400,000/mm3). He was diagnosed as having PMR because he fulfilled the standard criteria5. Then he was treated with oral prednisolone 15 mg daily, pantoprazol (PPI) 2 × 40 mg intravenous/day, MTX 15 mg subcutaneous/week, and folic acid 5 mg/week. Symptoms improved within 48 hours with no evidence for re-bleeding. ESR and CRP values decreased in 7 days and the steroid dose was reduced to 7.5 mg; 3 weeks later steroid dose was reduced to 5 mg. He was followed with subcutaneous MTX 15 mg, oral PPI, and deltacortril 5 mg treatment for 4.5 months. After that his steroid therapy was stopped completely and he has been followed without relapse for 6 months.

PMR is seen in older age groups who may have many comorbid diseases. This situation makes patients’ treatment and followup difficult. We suggest that MTX can be effective in treatment of PMR when the drug is started at disease onset, to avoid side effects of steroid therapy.

REFERENCES

  1. 1.↵
    1. Mazzantini M,
    2. Torre C,
    3. Miccoli M,
    4. Baggiani A,
    5. Talarico R,
    6. Bombardieri S,
    7. et al.
    Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: A retrospective study. J Rheumatol 2012;39:552–7.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Gonzalez-Gay MA,
    2. Vazquez-Rodriguez TR,
    3. Lopez-Diaz MJ
    . Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454–6.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Van der Veen MJ,
    2. Dinant HJ,
    3. van Booma-Frankfort C,
    4. van Albada-Kuipers GA,
    5. Bijlsma JW
    . Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218–23.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Caporali R,
    2. Cimmino MA,
    3. Ferraccioli G,
    4. Gerli R,
    5. Klersy C,
    6. Salvarani C,
    7. et al.
    Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493–500.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Bhaskar D
    . Concise guidance: Diagnosis and management of polymyalgia rheumatica. Clin Med 2010;10:270–4.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 8
1 Aug 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Difficult Case of Polymyalgia Rheumatica
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
A Difficult Case of Polymyalgia Rheumatica
OZGUR ZELIHA KARAAHMET, AJDA BAL, ECE UNLU, AYTUL CAKCI
The Journal of Rheumatology Aug 2012, 39 (8) 1758; DOI: 10.3899/jrheum.120146

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
A Difficult Case of Polymyalgia Rheumatica
OZGUR ZELIHA KARAAHMET, AJDA BAL, ECE UNLU, AYTUL CAKCI
The Journal of Rheumatology Aug 2012, 39 (8) 1758; DOI: 10.3899/jrheum.120146
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Modifications of Cardiovascular Risk Scores, But Not Standard Risk Scores, Improve Identification of Asymptomatic Coronary Artery Disease in Psoriatic Arthritis
  • Dr. Tam, et al, reply
  • Gottron Sign with Ulceration Is Not a Poor Prognostic Factor in Patients with Dermatomyositis and Interstitial Lung Disease
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • AV Rheum

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire